Yupelri (Revefenacin) Patent Expiration, LOE Window & CMS Spending

Yupelri (Revefenacin) by Viatris: FDA Orange Book core substance LOE 2031-08-25 (last listed 2039-10-23), 0 AB generics, $27.2M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN210598 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-08-25
Last Listed Patent or Exclusivity Date2039-10-23
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$27.2M
2024 Medicare Part D Spend$7.2M
2024 Medicaid Spend$20.0M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 29.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.